Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access
pharmaphorum
JANUARY 21, 2022
And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. Transformative, lifesaving products are available at increasingly high and unsustainable prices. WHO is OMI?
52 
Let's personalize your content